A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndromeOliver Groß, Markus Feldkoetter, Kay Latta et al.|Kidney International|2020Cited by 151
Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatmentShazia Ashraf, Assel Rakhmetova, Hiroki Kudo et al.|Nature Communications|2018Cited by 126